http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2266584-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-312
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 1997-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2e59c62ee59f387a96ad174f607b6dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d65174b2126c170ce9fe09049c91e41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1613fdb21e07105ccb5419ea3959c9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b78c6078a325068c6626732c70bba7c9
publicationDate 1998-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2266584-A1
titleOfInvention Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
abstract The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.
priorityDate 1996-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551227
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426107179
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419560480
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6437081
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73437561
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID168614

Total number of triples: 35.